Retatrutide is still an investigational medication in trials and isnt FDA-approved yet
Some people find their rhythm improves if they keep regular mealtimes and gentle physical activity during treatment, helping stabilise energy levels as their metabolism adjusts
Discussion Aside from the top 10% of responders in our real-world study, we found that GLP-1s resulted in smaller reductions in both weight loss and HbA1c, respectively
Application 15.2.5
Once approved, here is what the pricing landscape looks like based on comparable drugs: Semaglutide (Wegovy) without insurance runs $1,300 to $1,600 per month in the US Tirzepatide (Zepbound) without insurance runs $1,000 to $1,300 per month in the US Retatrutide, as a next-generation triple agonist, will likely land at $1,200 to $1,800 per month at launch In Australia, the UK, and Canada, prices tend to be lower due to government drug pricing controls